```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, functions as a valuable laboratory compound extensively employed in cardiovascular research . This monoclonal antibody fragment primarily targets the glycoprotein IIb/IIIa receptor on blood cells, blocking clot formation . Consequently , it's frequently applied as a tool to analyze the pathways underlying coagulation and to evaluate the effectiveness of anticoagulant therapies. Supply is typically controlled to institutional settings.
```
Abciximab Drug Research: Utilizing C7E3 and Compound 143653-53-6 in Research Investigations
Ongoing studies into abciximab, a GPIIb/IIIa, frequently employs the monoclonal protein C7E3 and the molecule identified as 143653-53-6. These reagents are essential for analyzing abciximab's mechanism of action, assessing its effectiveness in different patient populations, and understanding potential biomarkers of therapeutic success. Additional study leveraging these specific reagents is expected to provide valuable insights for enhancing patient care related to cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies website and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Analyzing Potential Avenues with the Drug Abciximab 143653-53-6 and C7E3
Recent work suggest that Abciximab (identified as 143653-53-6) presents significant research value, particularly when combined with the antibody fragment. Preliminary reports have that this pairing may boost patient responses in various heart-related conditions. Further exploration is directed on understanding the exact mechanism of effect between Abciximab and C7E3, involving analysis of blood clot aggregation and blood vessel safeguarding.
- Ongoing research endeavors intend to optimize delivery protocols.
- Animal models are are being employed to further confirm such theories.
- Clinical assessments might be required to fully assess therapeutic efficacy.
```
Abciximab (C7E3) for Research: Quality and Specifications (143653-53-6)
Researchers needing this antibody for in vitro studies should rigorously evaluate integrity and defined parameters . This product is typically offered as a solid powder and thorough analytical data including assessment by HPLC , biological activity assays, and endotoxin level testing are available. Ensure the manufacturer's CoA outlines acceptable values for contaminants and conforms to established QC standards .
High-Purity C7E3 Details & Stock
Acquiring analytical-grade Abciximab, specifically referencing the antibody C7E3 and identified by the chemical number 143653-53-6, requires detailed consideration of its origin . This antibody is frequently utilized in laboratory investigations , particularly those focused on platelet clumping and occlusion. Existing suppliers offer this material in varying amounts , typically ranging from g to substantial commercial amounts . Please advise reviewing the report of quality to verify integrity and suitability for your specific purpose. Additionally , confirm the expiration date before obtaining to maintain ideal efficacy .
- Typical Purity: >95%
- Storage Conditions: -20°C and suitable conditions
- Use : Platelet Adhesion Blocking Studies